Brolucizumab as Good as Aflibercept for Neovascular AMD

ByConnor Hodde

Brolucizumab is noninferior to aflibercept and requires less-frequent injections for patients with neovascular age-related macular degeneration (nAMD), according to results from two phase-3 trials. Earlier this month, Novartis announced that the U.S. Food and Drug Administration accepted the company’s brolucizumab application for the treatment of nAMD. Reductions in central subfield thickness (CST) on optical coherence tomography (OCT) from baseline to week 16 and to week 48 were significantly greater with brolucizumab than with aflibercept in both trials. (Click here to read the rest of the article)

Similar Posts

Retinal Remodeling And Metabolic Alterations in Human AMD

ByConnor Hodde

Age-related macular degeneration (AMD) is a progressive retinal degeneration resulting in central visual field loss, ultimately causing debilitating blindness.  While many genetic and environmental risk factors are known for AMD, we currently know less about the mechanisms mediating disease progression.  The goal of this article is to illustrate cell types impacted in AMD and demonstrate…

SOCS3 in retinal neurons and glial cells suppresses VEGF signaling to prevent pathological neovascular growth

ByConnor Hodde

Neurons and glial cells in the retina contribute to neovascularization, or the formation of abnormal new blood vessels, in proliferative retinopathy, a condition that can lead to vision loss or blindness. We identified a mechanism by which suppressor of cytokine signaling 3 (SOCS3) in neurons and glial cells prevents neovascularization. We found that Socs3 expression…

FDA approves first retinal implant for rare eye disease

ByConnor Hodde

The U.S. Food and Drug Administration has approved the first artificial retina, an implanted device that replicates some of the function of the retina, helping to restore vision to people blinded with a rare genetic disorder. The device is intended to replace the function of light-sensing cells in the retina destroyed by retinitis pigmentosa, an…

Nerve Injury Appears to be Root of Diabetes-related Vision Loss

ByConnor Hodde

Diabetes-related vision loss most often is blamed on blood vessel damage in and around the retina, but new research indicates that much of that vision loss may result from nerve cell injury that occurs long before any blood vessels are damaged.  After three months on a high-fat diet, the animals had developed obesity-related glucose intolerance,…

Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

ByConnor Hodde

Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…

Smart Contact Lens Helps Predict Disease Progression in Glaucoma Patients

ByConnor Hodde

A contact lens with a built-in sensor could help determine which glaucoma patients have a higher risk of disease progression, according to a new study.  Glaucoma remains a leading cause of blindness. One of the main indicators of the disease is high pressure in the eye, or intraocular pressure.  Researchers at Columbia tested the lenses on…